Chronic Hepatitis B infection

Chronic Hepatitis B (CHB) infection is defined as persistent detection of HBsAg for >6 months after initial exposure to the virus. Progression to chronic infection varies from:

- 90% among perinatally exposed (and unvaccinated) infants
- 30% among children age under 5 years
- <5% for adults.

The prolonged immunological response to infection can lead to the development of cirrhosis, liver failure, or hepatocellular carcinoma (HCC) over the long term.

Ideally, CHB patients should have suppressed HBV DNA levels <2,000 IU/mL (and ideally undetectable < 50 IU/mL) with ALT levels within the normal range.

The natural history of chronic HBV can be divided into 4 phases:

<table>
<thead>
<tr>
<th>IMMUNE TOLERANCE</th>
<th>IMMUNE CLEARANCE</th>
<th>IMMUNE CONTROL</th>
<th>IMMUNE ESCAPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>High HBV DNA, normal LFTs, HBeAg positive</td>
<td>High HBV DNA, abnormal LFTs, HBeAg positive</td>
<td>Low HBV DNA, normal LFTs, HBeAg negative</td>
<td>High HBV DNA, abnormal LFTs, HBeAg negative</td>
</tr>
<tr>
<td>Monitor every 6-12 months</td>
<td>At risk of progression to cirrhosis and HCC therefore should be referred for consideration of treatment</td>
<td>Monitor every 6-12 months</td>
<td>At risk of progression to cirrhosis and HCC therefore should be referred for consideration of treatment</td>
</tr>
</tbody>
</table>

Baseline testing recommended includes testing of liver function, full blood count, INR, alpha-fetoprotein (AFP), HBeAg/HBeAb*, HBV DNA (quantitative viral load), HCV antibody, hepatitis D virus antibody and antigen, HIV antigen/antibody, and hepatitis A IgG. Monitoring required every 6-12 months depending on phase.

*Both HBeAg and HBeAb can be negative in the presence of pre-core and core mutation in CHB with high viral replication.

Treatment

Referral to specialist for consideration of treatment if evidence of active disease (abnormal ALT, detectable HBV DNA > 2,000 IU/mL or evidence of chronic liver disease) or suspicion of immunosuppression or advanced liver disease.

Treatment consists of nucleoside / nucleotide analogue oral antiviral agents and/or pegylated interferon (IFN) injections. As the eradication of HBV infection is not achievable with currently available therapy, the primary aim of treatment is to maintain HBV DNA suppression (< 2,000 IU/mL) in order to prevent progressive liver injury.

Loss of HBsAg and seroconversion to anti-HBs constitutes a complete response. Loss of HBsAg is not common after therapy.

Loss of HBeAg and seroconversion to anti-HBe is associated with decreased viral replication and improved liver histology. Seroconversion to detectable HBeAg following treatment is reported in a significant number of patients if therapy is stopped soon after HBeAg becomes undetectable.

Complete recommendations and references can be found at the Gastroenterological Society of Australia website - www.gesa.org.au